Insider Transactions Reported by 22 Insiders of Adaptimmune Therapeutics PLC

Symbol
ADAPY on OTC
Location
Abingdon, Oxfordshire

Insiders trading volume in the past year

Adaptimmune Therapeutics PLC executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
EcoR1 Capital, LLC 10%+ Owner $10,247,969 -$6,890,236 -40% 28 Jul 2025
William Charles Bertrand Chief Operating Officer $102,997 28 Aug 2025
Garry E. Menzel Director $50,513 01 Jul 2024
Adrian Rawcliffe Chief Executive Officer, Director $25,745 20 Feb 2025
Cintia Piccina Chief Commercial Officer $10,588 20 Feb 2025
Elliot Norry Chief Medical Officer $4,362 20 Feb 2025
John Lunger Chief Patient Supply Officer $4,362 20 Feb 2025
Gavin Wood Chief Financial Officer $0 02 Sep 2025
Ali Behbahani Director $0 15 Aug 2025
John Furey Director 01 Jul 2024
Priti Hegde Director 01 Jul 2024
Helen Tayton-Martin Chief Business & Strgy Officer 15 Jan 2024
Andrew R. Allen Director 01 Jul 2024
James Noble Director 01 Jul 2022
Kristen Hege Director 01 Jul 2024
Barbara Gayle Duncan Director 01 Jul 2022
Charles Elliott Sigal Director 03 Jul 2023
DAVID M. MOTT Director 01 Jul 2024
Lawrence Alleva Director 01 Jul 2024
Tal Zvi Zaks Director 01 Jul 2022
Christopher James Hill Chief Financial Officer 10 Sep 2025
Joanna Brewer Chief Scientific Officer 20 Feb 2025

Recent Insider Transactions by Companies or Individuals for Adaptimmune Therapeutics PLC

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.